Biotech in Flanders: a stunning story
The Flemish biotech sector is world-renowned. Flanders is a world player in ?life sciences?, the study of all life forms, and in particular in biotechnology, the practical application of that knowledge through technology. Thanks to a fruitful cross-fertilization between high quality healthcare, exce...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Kapellen
Witsand Publishers
[2023]
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Zusammenfassung: | The Flemish biotech sector is world-renowned. Flanders is a world player in ?life sciences?, the study of all life forms, and in particular in biotechnology, the practical application of that knowledge through technology. Thanks to a fruitful cross-fertilization between high quality healthcare, excellent scientific research, daring entrepreneurship, risky financing and a supportive government, an academic and industrial network has emerged in Flanders over the past forty years that is considered unique in Europe. ?Flanders Biotech Valley?, between Meuse and North Sea, has become synonymous with quality.0In those 40 years, Flemish researchers and pioneers have made discoveries that affect more than two million patients a year and are used daily in agriculture, labs and medical cabinets. Entrepreneurs and their teams have had hundreds of meetings to convince investors to back these Flemish innovations and their story over all those other investment proposals that landed on their desks. With success. More than 10 billion euros found its way through Euronext, Nasdaq, Easdaq or private investments to Flemish biotech companies. Every euro invested in the sector became at least four euros ten years later, and every euro the Flemish government invested in the research of the Flemish Institute of Biotechnology (VIB) is worth eleven euros today. Some sixty thousand people today work directly or through supporting jobs in the Flemish biotech sector. That is a stunning story, without question. 0This book is based on interviews with dozens of privileged witnesses to the story of Flemish biotech and on a great many public documents and reports. It answers questions such as: what is a cell and how did we evolve in half a century from the first tentative sketch of the DNA molecule to profound insights into the role of genes, proteins, sugars and fats and in disease and health of humans, animals and plants? |
| Beschreibung: | 397 Seiten Illustrationen 31 cm |
| ISBN: | 9789493292260 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV049534781 | ||
| 003 | DE-604 | ||
| 005 | 20240617 | ||
| 007 | t| | ||
| 008 | 240206s2023 xx a||| |||| 00||| eng d | ||
| 020 | |a 9789493292260 |9 978-94-9329-226-0 | ||
| 035 | |a (OCoLC)1443581206 | ||
| 035 | |a (DE-599)BVBBV049534781 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-210 | ||
| 084 | |a HIST |q DE-210 |2 fid | ||
| 100 | 1 | |a Bury, Jo |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Biotech in Flanders |b a stunning story |c Jo Bury - Johan Cardoen - Dirk Reyn |
| 264 | 1 | |a Kapellen |b Witsand Publishers |c [2023] | |
| 264 | 4 | |c ©2023 | |
| 300 | |a 397 Seiten |b Illustrationen |c 31 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 520 | 3 | |a The Flemish biotech sector is world-renowned. Flanders is a world player in ?life sciences?, the study of all life forms, and in particular in biotechnology, the practical application of that knowledge through technology. Thanks to a fruitful cross-fertilization between high quality healthcare, excellent scientific research, daring entrepreneurship, risky financing and a supportive government, an academic and industrial network has emerged in Flanders over the past forty years that is considered unique in Europe. ?Flanders Biotech Valley?, between Meuse and North Sea, has become synonymous with quality.0In those 40 years, Flemish researchers and pioneers have made discoveries that affect more than two million patients a year and are used daily in agriculture, labs and medical cabinets. Entrepreneurs and their teams have had hundreds of meetings to convince investors to back these Flemish innovations and their story over all those other investment proposals that landed on their desks. With success. More than 10 billion euros found its way through Euronext, Nasdaq, Easdaq or private investments to Flemish biotech companies. Every euro invested in the sector became at least four euros ten years later, and every euro the Flemish government invested in the research of the Flemish Institute of Biotechnology (VIB) is worth eleven euros today. Some sixty thousand people today work directly or through supporting jobs in the Flemish biotech sector. That is a stunning story, without question. 0This book is based on interviews with dozens of privileged witnesses to the story of Flemish biotech and on a great many public documents and reports. It answers questions such as: what is a cell and how did we evolve in half a century from the first tentative sketch of the DNA molecule to profound insights into the role of genes, proteins, sugars and fats and in disease and health of humans, animals and plants? | |
| 648 | 7 | |a Geschichte 1980-2023 |2 gnd |9 rswk-swf | |
| 650 | 0 | 7 | |a Biotechnologie |0 (DE-588)4069491-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Biotechnologische Industrie |0 (DE-588)4208106-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Wissenschaftlicher Fortschritt |0 (DE-588)4190101-0 |2 gnd |9 rswk-swf |
| 651 | 7 | |a Flandern |0 (DE-588)4071249-7 |2 gnd |9 rswk-swf | |
| 651 | 7 | |a Belgien |0 (DE-588)4005406-8 |2 gnd |9 rswk-swf | |
| 689 | 0 | 0 | |a Belgien |0 (DE-588)4005406-8 |D g |
| 689 | 0 | 1 | |a Flandern |0 (DE-588)4071249-7 |D g |
| 689 | 0 | 2 | |a Biotechnologie |0 (DE-588)4069491-4 |D s |
| 689 | 0 | 3 | |a Biotechnologische Industrie |0 (DE-588)4208106-3 |D s |
| 689 | 0 | 4 | |a Wissenschaftlicher Fortschritt |0 (DE-588)4190101-0 |D s |
| 689 | 0 | 5 | |a Geschichte 1980-2023 |A z |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Cardoen, Johan |e Verfasser |4 aut | |
| 700 | 1 | |a Reyn, Dirk |e Verfasser |4 aut | |
| 856 | 4 | 2 | |m Digitalisierung Deutsches Museum |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034880318&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-034880318 | |
Datensatz im Suchindex
| _version_ | 1821871176888090624 |
|---|---|
| adam_text |
C
ONTENTS
P
REFACES
12
I
NTRODUCTION - BIOLOGY IS EVERYWHERE . AND TECHNOLOGY FOLLOWS IN ITS
FOOTSTEPS
A
LANDSCAPE OF SCIENCE
K
NOWING, BEING ABLE, DOING
A
RICH ECOSYSTEM
C
HAPTER 1 - ON THE SHOULDERS OF GIANTS
T
HE DOUBLE HELIX
NOBLE ROOTS
JULES BORD ET - FROM BASIC RESEARCHER TO VACCINE PRODUCER
FROM ANTIBODIES AND COMPLEMENT FACTORS .
.
. TO A SERIES OF DIAGNOSTIC TESTS .
.
. TO A VACCINE AGAINST PERTUSSIS .
.
. AND IN RECOGNITION A NOBEL PRIZE
J
EAN BRACHET - FROM ANIMAL DNA AND PLANT RNA
TO CENTRAL DOGMA
DON'T BELIEVE EVERYTHING YOU READ IN BOOKS
T
HE DOGMA OF MOLECULAR BIOLOGY
A CRUCIAL EXPERIMENT
T
HE GROUPE RHODE
CHRISTIAN DE DUVE - THE CELL DISSECTED
AN ACCIDENTAL DISCOVERY CONSIGNS INSULIN RESEARCH
T
O THE WASTEPAPER BASKET
NOBEL PRIZE FOR LYSOSOMES
PIET(ER) DE SOMER - ENTREPRENEUR, PHYSICIAN AND RESEARCHER
FROM 'BALATUM' TO 'PENICILLIN MADE IN BELGIUM'
R
.I.T. AND GSK VACCINES
THE REGA INSTITUTE - AN INDEPENDENT RESEARCH INSTITUTE
A POWERHOUSE FOR ANTIVIRAL DRUGS
P
AUL JANSSEN - WORLD CHAMPION IN DRUG DEVELOPMENT
APPRENTICESHIP IN THE US AND WITH CORNEILLE HEYMANS
A
DRUG RESEARCH COMPANY
M
ORE THAN SEVENTY DRUGS
THE GENIUS OF PAUL JANSSEN
DR. PAUL: "WHAT'S NEW?"
A COOL LOVER OF BIOTECH
C
ENTER FOR MOLECULAR DESIGN
T
HE LIFE OF THE CELL - PART 1: EXPEDITION TO THE INTERIOR OF THE CELL
C
HAPTER 2 - FOUNDERS OF FLEMISH BIOTECH
I
N THE FOOTSTEPS OF WATSON AND CRICK
W
ALTER FIERS - MOLECULAR BIOENGINEER 'AVANT LA LETTRE'
GODFATHER OF MODERN GENOM ICS
INTERFERON, INTERLEUKIN AND THE HUMAN IMMUNE SYSTEM
THE ENTREPRENEUR IN WALTER FIERS
FOCUS ON INFLUENZA
1
7
1
8
1
8
21
2
3
23
25
25
25
27
27
27
29
2
9
30
31
32
33
33
3
5
37
37
38
39
42
43
43
45
46
47
49
49
50
5
2
5
9
59
61
61
63
64
64
J
EFF SCHELL
MARC VAN MONTAGU
D
ESIRE COLLEN - RESEARCHER, PHYSICIAN, ENTREPRENEUR, PHILANTROPIST
AND FINANCIER
FROM LABORATORY CONCEPT TOT POTENTIAL MEDICINE
A
CHANCE MEETING - 'THE DAUGHTER OF A GUEST SPEAKER'
R
ECOGNIZED AS A MEDICINE
R
OYALTIES FOR SPIN-OFF CREATION AND SOCIETAL ADDED VALUE
H
ERMAN VAN DEN BERG HE - PIONEER IN HUMAN GENETICS
F
ROM THE BASEMENT OF THE HOSPITAL
P
OLICY MAKER BEHIND THE SCENES
T
HE LIFE OF THE CELL - PART 2: THE LANGUAGE OF LIFE
C
HAPTER 3 - THE ENTREPRENEURIAL RESEARCH UNIVERSITY
FROM THE UNIVERSITAS .
.
. TO THE RESEARCHING UNIVERSITY .
.
. TO THE TRIPLE HELIX FOR INNOVATION
S
TANFORD UNIVERSITY - CLASSIC EXAMPLE OF THE TRIPLE HELIX
THE FIRST TECH TRANSFER OFFICES
TECH TRANSFER AND BIOTECH
T
HE EUROPEAN PARADOX
TECH TRANSFER IN BELGIUM - LRD AS PIONEER
C
HAPTER 4 - THE FIRST FLEMISH BIOTECH COMPANIES
D
IRV PROVIDES THE TAILWIND
A GRIM PERIOD
F
LANDERS TECHNOLOGY INTERNATIONAL
A
NEW INDUSTRIAL CONTEXT FOR BIOTECHNOLOGY
P
LANT GENETIC SYSTEMS, GENETIC ACCESS TO THE KINGDOM OF PLANTS
PLASMID ON THE MAP
T
HE PLASMID PUZZLE
PLASMID WORLD NEWS
BUSINESS AND PATENTS
A
GREEN FUTURE
B
IOGENT, A FIRST INTRODUCTION TO THE 'RED' BIOTECH INDUSTRY IN FLANDERS
F
IERS' ACADEMIC CLONING MACHINE TURNED INTO A COMPANY
L
NNOGENETICS, THE LARGEST EUROPEAN BIOTECH OF ITS TIME
H
ARVESTING FROM ACADEMICS AND SEEKING FUNDING
T
HERANOSTICS - AN INNOVATIVE MODEL
REVENUE OVER CAPITAL CONTRIBUTION - AND THEN GO PUBLIC
THE THERAPEUTIC ARM
PHENOMENAL GROWTH .
.
. UNTIL THE FIRST CRACKS SHOW THEMSELVES
A
LL HOPE IN THE HEPATITIS C-VACCINE
TAKEOVER AFTER TAKEOVER
T
HE LEGACY OF PGS AND LNNOGENETICS . THE BEGINNING OF AN ECOSYSTEM
6
7
69
73
7
3
74
75
76
77
77
79
8
1
8
9
89
89
91
93
94
94
94
97
9
9
99
99
1
00
1
00
1
02
1
03
1
05
1
06
1
07
1
08
1
11
112
1
15
1
15
1
16
118
120
1
21
1
21
1
22
1
23
1
24
C
HAPTER 5 - VIB, THE FLEMISH INSTITUTE FOR BIOTECHNOLOGY
A
STRIKE, A DEMONSTRATION AND A THEATER IN MECHELEN
A
NEW COMPETENCE CENTER
S
TARTING FROM A BLANK SHEET OF PAPER .
AN INSTITUTE WITHOUT ANY WALLS
A
N INGENIOUS DUO JOB
A BUMPY START, FROM STRATEGIC PLANS TO THE CAMBRIDGE MODEL
S
TILL, A FLYING START, ALSO IN TECHNOLOGY TRANSFER
THE SPIDER IN THE BIOTECH WEB
OUTSTANDING INTERNATIONAL SCIENCE .
. SUPPORTED BY STATE-OF-THE-ART TECHNOLOGY
O
WN WALLS AFTER ALL: INCUBATORS, ACCELERATORS, OWN LABS
TECHNOLOGY TRANSFER AND VALUE CREATION
2
5 YEARS OF IMPACT
C
HAPTER 6 - THE ABCS OF FINANCING BIOTECH
C
OOKING COSTS MONEY
ONLY COSTS, NOT REVENUES
EUREKA! . AND THEN?
F
IRST ACTION IS PROTECTION
M
AKING A CHOICE - LICENSING OR STARTING A SPIN-OFF?
S
EED MONEY FINANCING
BANKS AND FFF'S
G
OVERNMENT PIONEERS WITH GLFVFV IN START-UP FINANCING
T
ECH TRANSFER OFFICES
S
CHOLARSHIPS AND GRANTS
THE HELPING HANDS OF THE FLEMISH GOVERNMENT
FEDERAL TAX SUPPORT FOR INNOVATION
E
UROPE'S HORIZON
V
ENTURE CAPITAL
B
USINESS ANGELS
V
ENTURE CAPITAL AND PRIVATE EQUITY
V
ENTURE CAPITAL ACTIVE IN THE FLEMISH ECOSYSTEM
G
OVERNMENT 'VENTURING' TOO
FROM SEED OVER SERIES A TO . ?
S
TAY ON BOARD OR GET OUT?
GROWTH FUNDS
GOING PUBLIC
E
ASDAQ, THE FIRST PAN-EUROPEAN TECH EXCHANGE, WITH FLEMISH ROOTS
S
TRATEGIC COLLABORATIONS AND ALLIANCES
MERGERS AND ACQUISITIONS
EVERY FINANCING HAS ITS ADVANTAGES AND DISADVANTAGES
S
TILL A ROLE FOR (INVESTMENT) BANKS?
MONEY IN ABUNDANCE, AND YET .
A
CRUCIAL TRANSITION PHASE
S
ITTING ON THE FENCE
1
27
1
27
1
29
1
29
1
31
1
32
1
33
1
35
1
36
1
36
1
37
1
39
1
39
1
41
1
45
1
45
1
45
1
47
1
48
1
49
1
50
1
50
1
51
1
53
1
53
1
54
1
56
1
57
1
58
1
59
1
61
1
62
1
64
1
65
1
67
1
68
1
68
1
71
1
74
1
75
1
77
1
77
1
79
1
80
1
81
C
HAPTER 7 - THE GREAT BIOTECH WAVE
ON THE FAST TRACK
F
UNCTIONAL GENOMICS: IN THE SLIPSTREAM OF THE GENOME PROJECTS
D
EVGEN, FROM GENOME SCREENER FOR PHARMA COMPANIES TO RICE ENHANCER
C
.ELEGANS, AN UNSIGHTLY ROUNDWORM AS A MODEL ORGANISM
RNA INTERFERENCE
R
ESEARCHER BECOMES CEO BY NECESSITY
D
EVGEN THERAPEUTICS AND DEVGEN CROP PROTECTION
T
RANSFORMATIVE DEAL WITH MONSANTO
AN IRRESISTIBLE OFFER
T
IBOTEC EN VIREO, PERSONALIZED MEDICINE FOR HIV
A
N EPIDEMIC HOLDING EVERYONE SPELLBOUND
D
R. PAUL'S LAST MAJOR CONCERN
R
OBOT CONQUERS THE LAB
R
APID BUILD-UP OF RESISTANCE
M
OST IMPORTANT HIV DATABASE WORLDWIDE
A
SHORTAGE OFFUNDS
B
IOCARTIS, RAPID AND DECENTRALIZED DNA DIAGNOSTICS
P
OCKET LABORATORIES
G
OING PUBLIC NOW
M
ULTIPLICOM, ALGORITHM AT THE BASE OF A DIAGNOSTICS COMPANY
F
ROM CE MARKING .
.
. TO NIP TESTING
T
EN TIMES THE STAKES
G
ALAPAGOS, BIOLOGICAL EXPLORERS
T
HE PROMISE .
COLD VIRUS AS A SHUTTLE VEHICLE
CRUCIAL FLEMISH START-UP FUNDING AND THIRD-PARTY SERVICES
PROPRIETARY DEVELOPMENT:JAKS AND THE BIRTH OFFILGOTINIB
2
005, THE YEAR OF'NOTHING VENTURED, NOTHING GAINED'?
SUCCESSIVE PARTNERSHIPS FOR RHEUMATOID ARTHRITIS
ON TO THE MAGICAL YEAR 2019 - APPROVAL AND THE 3.5 BILLION DEAL
LIKE A BOLT FROM THE BLUE
A
NEW STANDARD-BEARER
H
EALING WITH PROTEINS AND CELLS
T
HROMBX AND THROMBOGENICS, FROM T-PA FOR THE POOR TO EYE DRUGS
A BYPRODUCT OFYAKULT
F
IFTY WORKING YEARS CONDENSED INTO THREE CALENDAR YEARS
P
ROTEIN PRODUCTION AND MONEY
THROMBOGENICS
A SUCCESFUL IPO - WITH 'DESIRE' IN THE BACKGROUND
P
EAK YEARS
G
REAT ADDED VALUE FOR PATIENTS
D-DAY FOR JETREA
S
ALES ARE NOT SUCCESFUL, SHARE PRICE COLLAPSES
PROTEIN DRUGS BY OTHER BIOTECHS
AELIN THERAPEUTICS, TURNING THE WORLD UPSIDE DOWN
A
GAINST CANCER AND INFECTIONS
1
85
1
85
1
88
1
89
1
89
1
91
1
92
1
93
1
94
1
94
1
95
1
95
1
97
1
97
1
99
2
00
201
203
203
2
04
205
205
206
2
07
209
210
211
2
12
213
214
215
2
17
218
220
2
21
2
23
223
224
224
2
25
225
227
228
2
29
230
232
232
O
RIONIS BIOSCIENCES, NEWLY DESIGNED SIGNALING PROTEINS LEAD DEFENSE
AGAINST CANCER
TIGENIX, PIONEER IN STEM CELL THERAPY
FOCUS ON CARTILAGE AND JOINTS - SOMETHING ABSOLUTELY NEW
A
MERGER AND A MODIFIED STRATEGY
I
NTEREST FROM JAPAN
CST, CELL THERAPY FOR ANIMALS TOO
ACTOGENIX, WORKING WITH LACTIC ACID BACTERIA
L
ACTIC ACID BACTERIA AND THERAPEUTIC PROTEINS
TRAPPED FOR DAYS
ROCK-SOLID FOUNDATIONS
N
EW TECHNOLOGY
=
UNSUSPECTED CHALLENGES
F
ROM A PARTNER TO PRECIGEN ACTOBIO
M
RM HEALTH, 'BUGS AS DRUGS'
T
HE LIFE OF THE CELL - PART 3: AUTO/VFATION, /VFLNIATURIZATION AND
DIGITIZATION
F
RO/VF FIELD TO FORK, THE GREEN BRANCH OF BIO TECH
T
HE LEGACY OF PCS AND MARC VAN MONTAGU
THE USEFUL HYBRID
CROPDESIGN, BETTING ON SYSTEMS BIOLOGY OF PLANTS
FUSION, BRANCHING AND FERTILIZATION
G
ROWTH AND FLOWERING OF A GREEN ECOSYSTEM
DEEP IN THE CELLS OF PLANTS
C
LOSING THE CIRCLE
P
LANT GENES ON THE (SOCIETAL) FIELD
C
A/VFELS, LLA/VFAS, ANTIBODIES, NANOBODIES AND DERIVATIVES
-
A SEQUOIA IN THE ECOSYSTE/VF
S
TUBBORN STUDENTS CAUSE UNINTENDED MAJOR BREAKTHROUGH
C
AMEL BLOOD FROM THE FREEZER
IN SEARCH OF A CAMEL
V
ALORIZATION, AN UNKNOWN ACTIVITY AT THE UNIVERSITY
T
HEN LET'S APPLY FOR A PATENT OURSELVES .
WASHING POWDER WITH NANOBODIES
VIB STEPS INTO THE BREACH
A
BLYNX, PIONEERING WITH NANOBODIES
A
BOLT FROM THE BLUE
T
HE DEMISE OF A FLEMISH GEM?
T
HE ARGONAUTS OF ARGENX
INNOVATIVE AND AMBITIOUS, YET DIFFICULT AT THE BEGINNING
S
IMPLE ANTIBODY PLATFORM
BETTING ON BRAND NEW TARGETS
FCRN RECEPTOR AND MYASTHENIA GRAVIS AS LEADING EXAMPLES
F
ROM NEW GUEST AT THE TABLE TO APPROVAL FOR MARKET LAUNCH
O
THER FLAGSHIP PRODUCTS
AN INVESTMENT PATH FULL OF THORNS
M
AKING THE IMPOSSIBLE POSSIBLE
R
ARE DISEASES
2
34
2
35
236
237
238
2
39
240
240
241
2
42
242
243
244
2
46
2
52
2
52
254
255
257
2
59
261
262
2
65
2
67
2
67
267
268
269
2
69
269
270
271
2
77
278
280
280
2
83
283
283
284
2
85
285
288
288
T
HE REAL SATISFACTION
289
N
EW SHOOTS ON THE SEQUOIA
290
S
USTAINABLE AGRICULTURE THANKS TO LLAMAS FROM BIOTALYS
292
B
IOTECH VETERANS TACKLE 'POURRITURE GRISE'
292
R
EINVENTING FOOD PROTECTION
293
2
021 - A 'GRAND CRU' YEAR
294
S
UPPORT FROM UNEXPECTED QUARTERS
295
A
LFA BODIES, SYNTHETIC TARGET FINDERS
295
D
EEP INTO THE CELL
295
A
BIOINFORMATICIAN AND A SERIAL BIOTECH ENTREPRENEUR
296
S
/VFALL /VFOLECULES, BIG 1/VF PACT
299
B
IOTECHNOLOGY CHANGES R&D STRATEGY OF BIG PHARMA COMPANIES IN THE 1990S
299
J
ANSSEN PHARMACEUTICA AND ITS SPIN-OUTS: TIBOTEC, BARRIER, MOVETIS
301
AND PHARMANEUROBOOST
A
MERICAN INVESTORS IN BARRIER GET TO KNOW FLANDERS
302
M
OVETIS OR HOW PERSISTENCE BRINGS AN 'ABANDONED' PRODUCT TO THE PATIENT
303
P
HARMANEUROBOOST: EVEN SMALL MOLECULES ARE NO GUARANTEE FOR SUCCESS
307
OKAPI SCIENCES OR HOW ANIMALS ALSO BENEFIT FROM SMALL MOLECULES
307
R
EMYND: TACKLING ALZHEIMER'S DISEASE WITH SMALL MOLECULES
309
I
L
I
L
T
HE LIFE OF THE CELL - PART 4: KNOWING, BEING ABLE, DOING
.
CHAPTER 8 - THE NETWORK OF NETWORKS
T
HE INVISIBLE NETWORK AS A BREEDING GROUND
LMEC AS A JUNCTION BETWEEN MEDICINES AND MEDICAL TECHNOLOGY
D
ATA EN VITO AS TANGENT TO BIOTECHNOLOGY
V
IA BIOTECHNOLOGY AND ITC TOWARDS SOLUTIONS TO TROPICAL DISEASES
I
LVO, THE FOOD ISSUE AND A NEW AGRO-INCUBATOR
T
OWARDS MORE SUSTAINABLE FOOD SOURCES THROUGH BIOTECHNOLOGY - THE
PROTELNN CLUB
J
LABS AS AN ADDITIONAL BREEDING GROUND FOR IDEAS - BOTH WORLDWIDE AND IN
FLANDERS
CONFIDENCE AND UNDERSTANDING
F
LANDERS.BIO AS CATALYST OF THE ECOSYSTE/VF
C
HAPTER 9 - THE DYNAMICS OF THE FLEMISH BIOTECH ECOSYSTEM: A BIRD'S EYE
VIEW:
HOW THE PUZZLE PIECES FIT TOGETHER
M
ORE THAN THREE HUNDRED COMPANIES AND PARTNERS
T
HE FOUNDATIONS OF THE FLEMISH BIOTECH ECOSYSTEM
F
OUNDATION 1 - AN EXCEPTIONALLY BROAD KNOWLEDGE BASE
F
OUNDATION 2 - STRONG AND ABOVE ALL SUSTAINABLE FUNDING FOR
F
UNDAMENTAL ACADEMIC RESEARCH
FOUNDATION 3 - A LONG TRADITION OF FOCUS ON VALORIZATION AT
K
NOWLEDGE INSTITUTIONS
F
OUNDATION 4 - A CLEVERLY INVESTING GOVERNMENT: A POLICY
A
IMED AT SUPPORTING INNOVATION AND MARKET ORIENTED RESEARCH
FOUNDATION 5 - UNIQUE CROSS-FERTILIZATION WITH PHARMA AND
A
GROTECH PLAYERS
FOUNDATION 6 - HOME TO A LARGE NUMBER AND BROAD SPECTRUM OF
Q
UALITY CLINICAL STUDIES
FOUNDATION 7 - VIB, A UNIQUE SPIDER IN THE WEB
F
OUNDATION 8 - A HEALTHY AND COMPREHENSIVE INVESTMENT STORY
F
OUNDATION 9 - EURONEXT BRUSSEL
3
11
3
21
321
321
325
326
3
28
331
334
338
3
39
3
47
3
47
348
348
349
3
50
3
51
3
52
3
53
3
54
355
357
F
OUNDATION 10 - A BROAD DIVERSITY OF PROFESSIONAL SERVICES AND
C
OMPETENCES ARE PART OF THE ECOSYSTEM
FOUNDATION 11 - ACCES TO A POOL OF WELL-TRAINED YOUNG TALENTS
F
OUNDATION 12 - MODERN INFRASTRUCTURE FOR RESEARCH AND DEVELOPMENT
F
OUNDATION 13 - A STRONG NETWORK WITH INTERNATIONAL EXPERIENCE
A
ND DIMENSIONS
FOUNDATION 14 - SUCCESS STORIES GET ATTENTION AND INSPIRE
F
OUNDATION 15 - CONNECTING FEDERATIONS AND CLUSTERS,
W
ITH FLANDERS.BIO AT THE FOREFRONT
THE UNIQUE FLEMISH CEMENT: A STRATEGIC VISION,
DRIVEN BY AMBITION, SHAPED BY PRAGMATISM
T
EAFVF VESALIUS
C
HAPTER 10 - WHAT DOES IT BRING IN?
THE IVORY TOWER PULLED DOWN
SOCIAL VALUE ADDED
HELPING MORE THAN TWO MILLION PATIENTS A YEAR
M
ANY THOUSANDS OF ACRES
A HELPING HAND TO A SOCIETY WEIGHED DOWN WITH A PANDEMIC
G
ETTING BIOTECH WORK DONE IN FLANDERS (AND ELSEWHERE)
F
INANCIAL VALUE ADDED
ELEVEN EUROS RETURNED FOR EVERY EURO INVESTED IN VIS
R
EINVESTMENTS BY BIOTECH AND PHARMA INDUSTRIES
R
ETURN FOR FINANCIAL INVESTORS
A
TTRACTING DOMESTIC AND FOREIGN INVESTMENTS
A
EUROPEAN AMGEN?
F
LEMISH BIOTECH BRIO
E
PILOGUE - CHALLENGES AHEAD
A
N EVEN FASTER TRANSLATION OF INNOVATION TO BUSINESSES
F
LANDERS, AN IDEAL BREEDING GROUND FOR NEW COLLABORATIONS BETWEEN
B
IOTECH, ICT AND MEDTECH
WITH A MORE MATURE ECOSYSTEM, THE NEED FOR MORE GROWTH CAPITAL INCREASES
INCREASING ATTRACTIVENESS AND LIQUIDITY OF EURONEXT FOR BIOTECH / TECH
COMPANIES
CONTINUED NEED FOR A STABLE INVESTMENT CLIMATE
TIME TO ATTRACT, TRAIN AND RETAIN MORE TALENT
THE ROAD TO 2050
3
57
3
58
359
360
3
61
362
3
63
3
67
3
69
369
369
369
3
71
372
373
374
3
74
375
375
375
3
77
377
3
79
381
384
3
87
389
3
90
391
394
C
ONTRIBUTORS TO THIS BOOK
PROVIDED FINANCIAL SUPPORT FOR THIS BOOK
3
96
397
N
OTE ON THE AUTHORS
399 |
| adam_txt | |
| any_adam_object | 1 |
| any_adam_object_boolean | |
| author | Bury, Jo Cardoen, Johan Reyn, Dirk |
| author_facet | Bury, Jo Cardoen, Johan Reyn, Dirk |
| author_role | aut aut aut |
| author_sort | Bury, Jo |
| author_variant | j b jb j c jc d r dr |
| building | Verbundindex |
| bvnumber | BV049534781 |
| ctrlnum | (OCoLC)1443581206 (DE-599)BVBBV049534781 |
| era | Geschichte 1980-2023 gnd |
| era_facet | Geschichte 1980-2023 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV049534781</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20240617</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">240206s2023 xx a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789493292260</subfield><subfield code="9">978-94-9329-226-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1443581206</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV049534781</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-210</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">HIST</subfield><subfield code="q">DE-210</subfield><subfield code="2">fid</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bury, Jo</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biotech in Flanders</subfield><subfield code="b">a stunning story</subfield><subfield code="c">Jo Bury - Johan Cardoen - Dirk Reyn</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Kapellen</subfield><subfield code="b">Witsand Publishers</subfield><subfield code="c">[2023]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2023</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">397 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">31 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">The Flemish biotech sector is world-renowned. Flanders is a world player in ?life sciences?, the study of all life forms, and in particular in biotechnology, the practical application of that knowledge through technology. Thanks to a fruitful cross-fertilization between high quality healthcare, excellent scientific research, daring entrepreneurship, risky financing and a supportive government, an academic and industrial network has emerged in Flanders over the past forty years that is considered unique in Europe. ?Flanders Biotech Valley?, between Meuse and North Sea, has become synonymous with quality.0In those 40 years, Flemish researchers and pioneers have made discoveries that affect more than two million patients a year and are used daily in agriculture, labs and medical cabinets. Entrepreneurs and their teams have had hundreds of meetings to convince investors to back these Flemish innovations and their story over all those other investment proposals that landed on their desks. With success. More than 10 billion euros found its way through Euronext, Nasdaq, Easdaq or private investments to Flemish biotech companies. Every euro invested in the sector became at least four euros ten years later, and every euro the Flemish government invested in the research of the Flemish Institute of Biotechnology (VIB) is worth eleven euros today. Some sixty thousand people today work directly or through supporting jobs in the Flemish biotech sector. That is a stunning story, without question. 0This book is based on interviews with dozens of privileged witnesses to the story of Flemish biotech and on a great many public documents and reports. It answers questions such as: what is a cell and how did we evolve in half a century from the first tentative sketch of the DNA molecule to profound insights into the role of genes, proteins, sugars and fats and in disease and health of humans, animals and plants?</subfield></datafield><datafield tag="648" ind1=" " ind2="7"><subfield code="a">Geschichte 1980-2023</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biotechnologie</subfield><subfield code="0">(DE-588)4069491-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biotechnologische Industrie</subfield><subfield code="0">(DE-588)4208106-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wissenschaftlicher Fortschritt</subfield><subfield code="0">(DE-588)4190101-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">Flandern</subfield><subfield code="0">(DE-588)4071249-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">Belgien</subfield><subfield code="0">(DE-588)4005406-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Belgien</subfield><subfield code="0">(DE-588)4005406-8</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Flandern</subfield><subfield code="0">(DE-588)4071249-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Biotechnologie</subfield><subfield code="0">(DE-588)4069491-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Biotechnologische Industrie</subfield><subfield code="0">(DE-588)4208106-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="4"><subfield code="a">Wissenschaftlicher Fortschritt</subfield><subfield code="0">(DE-588)4190101-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="5"><subfield code="a">Geschichte 1980-2023</subfield><subfield code="A">z</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cardoen, Johan</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reyn, Dirk</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung Deutsches Museum</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034880318&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034880318</subfield></datafield></record></collection> |
| geographic | Flandern (DE-588)4071249-7 gnd Belgien (DE-588)4005406-8 gnd |
| geographic_facet | Flandern Belgien |
| id | DE-604.BV049534781 |
| illustrated | Illustrated |
| index_date | 2024-07-03T23:27:33Z |
| indexdate | 2025-01-21T15:02:29Z |
| institution | BVB |
| isbn | 9789493292260 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034880318 |
| oclc_num | 1443581206 |
| open_access_boolean | |
| owner | DE-210 |
| owner_facet | DE-210 |
| physical | 397 Seiten Illustrationen 31 cm |
| publishDate | 2023 |
| publishDateSearch | 2023 |
| publishDateSort | 2023 |
| publisher | Witsand Publishers |
| record_format | marc |
| spelling | Bury, Jo Verfasser aut Biotech in Flanders a stunning story Jo Bury - Johan Cardoen - Dirk Reyn Kapellen Witsand Publishers [2023] ©2023 397 Seiten Illustrationen 31 cm txt rdacontent n rdamedia nc rdacarrier The Flemish biotech sector is world-renowned. Flanders is a world player in ?life sciences?, the study of all life forms, and in particular in biotechnology, the practical application of that knowledge through technology. Thanks to a fruitful cross-fertilization between high quality healthcare, excellent scientific research, daring entrepreneurship, risky financing and a supportive government, an academic and industrial network has emerged in Flanders over the past forty years that is considered unique in Europe. ?Flanders Biotech Valley?, between Meuse and North Sea, has become synonymous with quality.0In those 40 years, Flemish researchers and pioneers have made discoveries that affect more than two million patients a year and are used daily in agriculture, labs and medical cabinets. Entrepreneurs and their teams have had hundreds of meetings to convince investors to back these Flemish innovations and their story over all those other investment proposals that landed on their desks. With success. More than 10 billion euros found its way through Euronext, Nasdaq, Easdaq or private investments to Flemish biotech companies. Every euro invested in the sector became at least four euros ten years later, and every euro the Flemish government invested in the research of the Flemish Institute of Biotechnology (VIB) is worth eleven euros today. Some sixty thousand people today work directly or through supporting jobs in the Flemish biotech sector. That is a stunning story, without question. 0This book is based on interviews with dozens of privileged witnesses to the story of Flemish biotech and on a great many public documents and reports. It answers questions such as: what is a cell and how did we evolve in half a century from the first tentative sketch of the DNA molecule to profound insights into the role of genes, proteins, sugars and fats and in disease and health of humans, animals and plants? Geschichte 1980-2023 gnd rswk-swf Biotechnologie (DE-588)4069491-4 gnd rswk-swf Biotechnologische Industrie (DE-588)4208106-3 gnd rswk-swf Wissenschaftlicher Fortschritt (DE-588)4190101-0 gnd rswk-swf Flandern (DE-588)4071249-7 gnd rswk-swf Belgien (DE-588)4005406-8 gnd rswk-swf Belgien (DE-588)4005406-8 g Flandern (DE-588)4071249-7 g Biotechnologie (DE-588)4069491-4 s Biotechnologische Industrie (DE-588)4208106-3 s Wissenschaftlicher Fortschritt (DE-588)4190101-0 s Geschichte 1980-2023 z DE-604 Cardoen, Johan Verfasser aut Reyn, Dirk Verfasser aut Digitalisierung Deutsches Museum application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034880318&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Bury, Jo Cardoen, Johan Reyn, Dirk Biotech in Flanders a stunning story Biotechnologie (DE-588)4069491-4 gnd Biotechnologische Industrie (DE-588)4208106-3 gnd Wissenschaftlicher Fortschritt (DE-588)4190101-0 gnd |
| subject_GND | (DE-588)4069491-4 (DE-588)4208106-3 (DE-588)4190101-0 (DE-588)4071249-7 (DE-588)4005406-8 |
| title | Biotech in Flanders a stunning story |
| title_auth | Biotech in Flanders a stunning story |
| title_exact_search | Biotech in Flanders a stunning story |
| title_exact_search_txtP | Biotech in Flanders. A stunning story |
| title_full | Biotech in Flanders a stunning story Jo Bury - Johan Cardoen - Dirk Reyn |
| title_fullStr | Biotech in Flanders a stunning story Jo Bury - Johan Cardoen - Dirk Reyn |
| title_full_unstemmed | Biotech in Flanders a stunning story Jo Bury - Johan Cardoen - Dirk Reyn |
| title_short | Biotech in Flanders |
| title_sort | biotech in flanders a stunning story |
| title_sub | a stunning story |
| topic | Biotechnologie (DE-588)4069491-4 gnd Biotechnologische Industrie (DE-588)4208106-3 gnd Wissenschaftlicher Fortschritt (DE-588)4190101-0 gnd |
| topic_facet | Biotechnologie Biotechnologische Industrie Wissenschaftlicher Fortschritt Flandern Belgien |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034880318&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT buryjo biotechinflandersastunningstory AT cardoenjohan biotechinflandersastunningstory AT reyndirk biotechinflandersastunningstory |